Neilesh B. Parikh
YOU?
Author Swipe
View article: Adoptive transfer of T lymphocytes retrovirally transduced to express personalized neoantigen reactive T cell receptors can mediate tumor regression in patients with metastatic colorectal cancer
Adoptive transfer of T lymphocytes retrovirally transduced to express personalized neoantigen reactive T cell receptors can mediate tumor regression in patients with metastatic colorectal cancer Open
Adoptive cell transfer (ACT) using neoantigen reactive T lymphocytes can mediate cancer regression. Here, we developed methods to isolate unique, personalized, neoantigen reactive T cell receptors (TCRs) from tumor infiltrating lymphocytes…
View article: 1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers Open
Background Immunotherapies represent promising approaches to treat metastatic solid tumors, yet their response rates remain low.1 2 Identifying antitumor T cells, their antigens, and their cognate T cell receptors (TCRs) can provide crucia…
View article: Cell surface marker-based capture of neoantigen-reactive CD8<sup>+</sup> T-cell receptors from metastatic tumor digests
Cell surface marker-based capture of neoantigen-reactive CD8<sup>+</sup> T-cell receptors from metastatic tumor digests Open
Background Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease. As the genetic engineering of …
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Data from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Data from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Purpose:Immune checkpoint blockade (ICB) agents and adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) are prominent immunotherapies used for the treatment of advanced melanoma. Both therapies rely on activation of lympho…
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Data from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Data from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Purpose:Immune checkpoint blockade (ICB) agents and adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) are prominent immunotherapies used for the treatment of advanced melanoma. Both therapies rely on activation of lympho…
View article: Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Supplementary Table from Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
View article: Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma Open
Purpose: Immune checkpoint blockade (ICB) agents and adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL) are prominent immunotherapies used for the treatment of advanced melanoma. Both therapies rely on activation of lymph…
View article: Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers
Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers Open
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tum…
View article: Early postoperative ERAS compliance predicts decreased length of stay and complications following liver resection
Early postoperative ERAS compliance predicts decreased length of stay and complications following liver resection Open
ERAS decreases LOS after liver resection. Nutritional advancement, drain discontinuation, multimodal and oral analgesia, and ambulation >100 ft by POD3 are associated with decreased LOS72. Achieving ≥6 components by POD3 predicts decreased…
View article: 167 High-efficiency capture of anti-tumor neoantigen-reactive T cell receptors from tumor digest
167 High-efficiency capture of anti-tumor neoantigen-reactive T cell receptors from tumor digest Open
Background As cellular immunotherapies utilizing genetically engineered T cells become a more significant focus of clinical investigation, identification of patient-specific neoantigen-reactive T cell receptors (TCRs) in a practical and ef…
View article: 651 Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction
651 Molecular signature of neoantigen-reactive CD4+ and CD8+ T cells from metastatic human cancers enables prospective antitumor TCR prediction Open
Background Autologous patient T cells engineered to express antitumor T cell receptors (TCRs) and chimeric antigen receptors (CARs) have been effective for the treatment of certain cancer types,1–4 and tumor neoantigens encoded by cancer-s…
View article: Inhibition of Vascular Endothelial Growth Factor Synthesis in Human Retinal Pigment Epithelial Cells by Pazopanib
Inhibition of Vascular Endothelial Growth Factor Synthesis in Human Retinal Pigment Epithelial Cells by Pazopanib Open
Age-related macular degeneration (AMD) is a leading cause of central vision blindness in most developed countries. Several new drugs are now available to attempt to prevent progression or treat AMD, however, they have limited effectiveness…